120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
心电图引导的抗心律失常治疗在急性冠状动脉综合征中的应用：生物标志物、心功能和生活质量的多维评估
Authors Li X, Liu X, Jing M, Yang C, Luo H, Li L
Received 20 November 2025
Accepted for publication 26 January 2026
Published 6 February 2026 Volume 2026:22 583212
DOI https://doi.org/10.2147/TCRM.S583212
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor De Yun Wang
Xiaolong Li,1,* Xianfeng Liu,2,* Ming Jing,3 Chengwu Yang,2 Haoxiang Luo,4 Long Li5
1Procurement Office, The People’s Hospital of Menghai County, Xishuangbanna Dai Autonomous Prefecture, 666200, People’s Republic of China; 2Medical Equipment Department, The People’s Hospital of Menghai County, Xishuangbanna Dai Autonomous Prefecture, 666200, People’s Republic of China; 3Tuina Department, Yuxi Municipal Hospital of Traditional Chinese Medicine, Yuxi, 653100, People’s Republic of China; 4Medical Equipment Department, Dali Bai Autonomous Prefecture Hospital of Traditional Chinese Medicine, Dali Bai Autonomous Prefecture, 671003, People’s Republic of China; 5Asset Management Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Long Li, Asset Management Department, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Avenue, Wuhua District, Kunming, Yunnan Province, 650101, People’s Republic of China, Email longkm2026@163.com Haoxiang Luo, Medical Equipment Department, Dali Bai Autonomous Prefecture Hospital of Traditional Chinese Medicine, No. 26, Longxi Road, Dali City, Dali Bai Autonomous Prefecture, Yunnan Province, 671003, People’s Republic of China, Email luo3212986@163.com
Objective: To evaluate the impact of electrocardiogram (ECG)-guided antiarrhythmic strategy on serum biomarkers, cardiac function, and quality of life in patients with acute coronary syndrome (ACS) and arrhythmias.
Methods: This prospective observational cohort enrolled 80 ACS patients with arrhythmias managed via a monitor-alert-response-titration pathway (observation group) during January-December 2024. Propensity score-matched controls (n = 80) received conventional experience-based antiarrhythmic therapy. Comparisons included in-hospital antiarrhythmic interventions, arrhythmia control, adverse events, and myocardial injury/stress biomarkers (NT-proBNP, hs-cTnI, hs-cTnT, hs-CRP) at T0 (baseline), T1 (2-day), and T2 (7-day). Cardiac function (LVEF, LVEDD, LVEDVI, E/e′) and patient-reported outcomes [Seattle Angina Questionnaire (SAQ), 6-minute walk test (6MWT)] were assessed at T0, T3 (1-month), and T4 (6-month). Major adverse cardiovascular events (MACE) were recorded over 6 months.
Results: The observation group demonstrated higher β-blocker utilization, guideline adherence, and drug adjustment rates (P < 0.05). Arrhythmia control was superior in the observation group at T2 (93.75% vs 82.50%, P < 0.05). More pronounced reductions in all biomarkers were observed in the observation group at T1 and T2 (P < 0.05). Greater improvements in LVEF, LVEDD, LVEDVI, E/e′, SAQ scores, and 6MWT distance were sustained in the observation group at T3 and T4 (P < 0.05). The 6-month MACE rate was lower in the observation group (13.75% vs 32.50%, P < 0.05).
Conclusion: ECG-guided antiarrhythmic therapy improves pharmacotherapy quality and arrhythmia control, accelerating myocardial injury and stress attenuation. This strategy approach enhances cardiac recovery, reverse remodeling, functional capacity, and quality of life, ultimately reducing long-term cardiovascular risk.
Keywords: acute coronary syndrome, ECG-guided antiarrhythmic therapy, cardiac function, biomarkers, quality of life
1Procurement Office, The People’s Hospital of Menghai County, Xishuangbanna Dai Autonomous Prefecture, 666200, People’s Republic of China; 2Medical Equipment Department, The People’s Hospital of Menghai County, Xishuangbanna Dai Autonomous Prefecture, 666200, People’s Republic of China; 3Tuina Department, Yuxi Municipal Hospital of Traditional Chinese Medicine, Yuxi, 653100, People’s Republic of China; 4Medical Equipment Department, Dali Bai Autonomous Prefecture Hospital of Traditional Chinese Medicine, Dali Bai Autonomous Prefecture, 671003, People’s Republic of China; 5Asset Management Department, The Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Long Li, Asset Management Department, The Second Affiliated Hospital of Kunming Medical University, No. 374, Dianmian Avenue, Wuhua District, Kunming, Yunnan Province, 650101, People’s Republic of China, Email longkm2026@163.com Haoxiang Luo, Medical Equipment Department, Dali Bai Autonomous Prefecture Hospital of Traditional Chinese Medicine, No. 26, Longxi Road, Dali City, Dali Bai Autonomous Prefecture, Yunnan Province, 671003, People’s Republic of China, Email luo3212986@163.com
Objective: To evaluate the impact of electrocardiogram (ECG)-guided antiarrhythmic strategy on serum biomarkers, cardiac function, and quality of life in patients with acute coronary syndrome (ACS) and arrhythmias.
Methods: This prospective observational cohort enrolled 80 ACS patients with arrhythmias managed via a monitor-alert-response-titration pathway (observation group) during January-December 2024. Propensity score-matched controls (n = 80) received conventional experience-based antiarrhythmic therapy. Comparisons included in-hospital antiarrhythmic interventions, arrhythmia control, adverse events, and myocardial injury/stress biomarkers (NT-proBNP, hs-cTnI, hs-cTnT, hs-CRP) at T0 (baseline), T1 (2-day), and T2 (7-day). Cardiac function (LVEF, LVEDD, LVEDVI, E/e′) and patient-reported outcomes [Seattle Angina Questionnaire (SAQ), 6-minute walk test (6MWT)] were assessed at T0, T3 (1-month), and T4 (6-month). Major adverse cardiovascular events (MACE) were recorded over 6 months.
Results: The observation group demonstrated higher β-blocker utilization, guideline adherence, and drug adjustment rates (P < 0.05). Arrhythmia control was superior in the observation group at T2 (93.75% vs 82.50%, P < 0.05). More pronounced reductions in all biomarkers were observed in the observation group at T1 and T2 (P < 0.05). Greater improvements in LVEF, LVEDD, LVEDVI, E/e′, SAQ scores, and 6MWT distance were sustained in the observation group at T3 and T4 (P < 0.05). The 6-month MACE rate was lower in the observation group (13.75% vs 32.50%, P < 0.05).
Conclusion: ECG-guided antiarrhythmic therapy improves pharmacotherapy quality and arrhythmia control, accelerating myocardial injury and stress attenuation. This strategy approach enhances cardiac recovery, reverse remodeling, functional capacity, and quality of life, ultimately reducing long-term cardiovascular risk.
Keywords: acute coronary syndrome, ECG-guided antiarrhythmic therapy, cardiac function, biomarkers, quality of life